Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company focused on transforming disease management by keeping people first—the patients who benefit from the information that our advanced diagnostic tests provide, the clinicians who use our tests to guide disease management decisions, our talented and valued employees, and our investors.
Our innovative portfolio of commercial and pipeline tests targets unmet clinical need along the patient care continuum. We currently market six proprietary tests designed to answer clinical questions and address treatment plan challenges facing physicians in dermatologic cancers, uveal melanoma, Barrett’s esophagus, and mental health. https://castletestinfo.com
Our test for invasive cutaneous melanoma, DecisionDx®-Melanoma, is a proprietary gene expression profile (GEP) test that uses an individual patient’s tumor biology to predict the risk of metastasis or recurrence, as well as the risk of sentinel lymph node positivity, independent of traditional staging factors. http://bit.ly/DDx-Melanoma
DecisionDx®-SCC is our GEP test that predicts the risk of metastasis in patients with cutaneous squamous cell carcinoma, who have one or more risk factors. https://bit.ly/DDx-SCC
DecisionDx®-UM, the standard of care in uveal melanoma staging, is our GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer. https://bit.ly/DDx-UM
Our comprehensive diagnostic offering — myPath® Melanoma and DiffDx®-Melanoma — provides a highly accurate, objective result to aid dermatopathologists and dermatologists in characterizing suspicious pigmented lesions. https://bit.ly/myPathDiffDx
TissueCypher® Barrett’s Esophagus is the world’s first precision medicine test designed to predict future development of esophageal cancer in patients with Barrett’s esophagus. https://tissuecypher.com
Castle Biosciences is based in Friendswood, TX and has laboratory operations in Phoenix, AZ, and Pittsburgh, PA.
|
|
|
501-1,000 employees
View all Castle Biosciences, Inc. employees
|
|
Biotechnology
|
|
505 S Friendswood Dr, Suite 401, Friendswood, Texas 77546, US
|
|
2008
|
|
Skin Cancer, Melanoma, Next Gen Sequencing, Cutaneous Melanoma, Diagnostic Cancer Testing, Uveal Melanoma, Barrett's Esophagus, Cutaneous Squamous Cell Carcinoma, Dermatologic Cancer, Esophageal Adenocarcinoma, Gene Expression Profile Tests
|
Sandra Newcomb is the CEO of Castle Biosciences, Inc.. To contact Sandra Newcomb email at [email protected].
The decision makers in Castle Biosciences, Inc. are Bob Cook, Derek Maetzold, Hillary Caruso, etc. Click to Find Castle Biosciences, Inc. decision makers emails.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.